CY1124717T1 - Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων - Google Patents

Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων

Info

Publication number
CY1124717T1
CY1124717T1 CY20211100943T CY211100943T CY1124717T1 CY 1124717 T1 CY1124717 T1 CY 1124717T1 CY 20211100943 T CY20211100943 T CY 20211100943T CY 211100943 T CY211100943 T CY 211100943T CY 1124717 T1 CY1124717 T1 CY 1124717T1
Authority
CY
Cyprus
Prior art keywords
kits
cells
provides
expansion
methods
Prior art date
Application number
CY20211100943T
Other languages
Greek (el)
English (en)
Inventor
Lothar Germeroth
Christian STEMBERGER
Original Assignee
Juno Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Gmbh filed Critical Juno Therapeutics Gmbh
Publication of CY1124717T1 publication Critical patent/CY1124717T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/48—Automatic or computerized control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
    • C12N2537/10—Cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Sustainable Development (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Computer Hardware Design (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Physics & Mathematics (AREA)
CY20211100943T 2014-04-16 2021-11-02 Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων CY1124717T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980506P 2014-04-16 2014-04-16
PCT/EP2015/058339 WO2015158868A2 (en) 2014-04-16 2015-04-16 Methods, kits and apparatus for expanding a population of cells

Publications (1)

Publication Number Publication Date
CY1124717T1 true CY1124717T1 (el) 2022-07-22

Family

ID=53052805

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100943T CY1124717T1 (el) 2014-04-16 2021-11-02 Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων

Country Status (27)

Country Link
US (2) US11274278B2 (cg-RX-API-DMAC7.html)
EP (2) EP3988920A1 (cg-RX-API-DMAC7.html)
JP (4) JP6696969B2 (cg-RX-API-DMAC7.html)
KR (2) KR102714469B1 (cg-RX-API-DMAC7.html)
CN (3) CN111961647A (cg-RX-API-DMAC7.html)
AU (2) AU2015248786B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016024072B1 (cg-RX-API-DMAC7.html)
CA (2) CA3176848A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124717T1 (cg-RX-API-DMAC7.html)
DK (1) DK3132247T3 (cg-RX-API-DMAC7.html)
ES (1) ES2892927T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211430T1 (cg-RX-API-DMAC7.html)
HU (1) HUE056852T2 (cg-RX-API-DMAC7.html)
IL (3) IL280738B (cg-RX-API-DMAC7.html)
LT (1) LT3132247T (cg-RX-API-DMAC7.html)
MX (2) MX380519B (cg-RX-API-DMAC7.html)
MY (1) MY184699A (cg-RX-API-DMAC7.html)
PH (2) PH12016502017B1 (cg-RX-API-DMAC7.html)
PL (1) PL3132247T3 (cg-RX-API-DMAC7.html)
PT (1) PT3132247T (cg-RX-API-DMAC7.html)
RS (1) RS62471B1 (cg-RX-API-DMAC7.html)
RU (2) RU2020133435A (cg-RX-API-DMAC7.html)
SA (3) SA520412247B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201808491UA (cg-RX-API-DMAC7.html)
SI (1) SI3132247T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100600T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015158868A2 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2817625B1 (en) 2012-02-23 2025-01-01 Juno Therapeutics GmbH Chromatographic isolation of cells and other complex biological materials
ES2892927T3 (es) * 2014-04-16 2022-02-07 Juno Therapeutics Gmbh Métodos, kits y aparatos para expandir una población de células
EP3134514B1 (en) 2014-04-23 2019-09-18 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MX395154B (es) 2015-10-22 2025-03-25 Juno Therapeutics Gmbh Métodos, kits, agentes y aparatos para transducción.
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
CN107129988A (zh) * 2016-02-29 2017-09-05 广西医科大学 一种特异性结合cd3的核酸适配体及其筛选方法和应用
JP2019526272A (ja) * 2016-06-02 2019-09-19 クロトー セラピューティクス インコーポレイテッドＫｌｏｔｈｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療用組換えクロトータンパク質ならびにそれを含む組成物および方法
KR20230107408A (ko) 2016-07-29 2023-07-14 주노 쎄러퓨티크스 인코퍼레이티드 항-cd19 항체에 대한 항-이디오타입 항체
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
CA3045338A1 (en) * 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
US11624046B2 (en) * 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (en) * 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US12234441B2 (en) * 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
BR112019022356A2 (pt) * 2017-04-27 2020-05-26 Juno Therapeutics Gmbh Reagentes de partícula oligoméricos e métodos de uso dos mesmos
ES2999361T3 (en) 2017-11-01 2025-02-25 Juno Therapeutics Inc Process for generating therapeutic compositions of engineered cells
AU2018385756B2 (en) * 2017-12-15 2025-10-09 Aleta Biotherapeutics Inc. CD19 variants
CN107904278B (zh) * 2017-12-25 2021-07-20 北昊干细胞与再生医学研究院有限公司 检测药物对细胞增殖影响的方法
US11149244B2 (en) * 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
CN112424342A (zh) * 2018-05-08 2021-02-26 生命科技公司 用于培养和扩增细胞的组合物和方法
WO2019226529A1 (en) * 2018-05-21 2019-11-28 Bioprocessia Technologies Llc Multivalent protein complexes
IL280659B2 (en) * 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
KR102884943B1 (ko) 2018-09-11 2025-11-12 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 개선된 항-flt3 항원 결합 단백질
EP3623383A1 (en) 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
EP3856888A4 (en) * 2018-09-24 2022-10-12 Southwest Research Institute THREE-DIMENSIONAL BIOREACTORS
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
KR20200132147A (ko) * 2019-05-15 2020-11-25 의료법인 성광의료재단 자연 살해 세포의 배양용 조성물 및 이를 이용한 방법
US20220241702A1 (en) * 2019-05-24 2022-08-04 Sol Bio Corporation Affinity isolation system and method using switch-like binding reaction
US20220228101A1 (en) * 2019-06-07 2022-07-21 Juno Therapeutics, Inc. Automated t cell culture
IL292319B1 (en) 2019-10-30 2025-09-01 C3S2 Gmbh Cell selection and/or stimulation devices and methods of use
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
KR20220122656A (ko) 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
CN115916817A (zh) 2019-12-06 2023-04-04 朱诺治疗学股份有限公司 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
US11965882B2 (en) 2020-01-31 2024-04-23 Cell.Copedia GmbH Methods of isolating a biological entity
IL295384A (en) 2020-02-12 2022-10-01 Juno Therapeutics Inc Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
KR20220152227A (ko) 2020-02-12 2022-11-15 주노 쎄러퓨티크스 인코퍼레이티드 Ｂｃｍａ-지시된 키메라 항원 수용체 ｔ 세포 조성물 및 이의 방법 및 용도
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
JP2023536326A (ja) 2020-08-05 2023-08-24 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CN117321417A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 确定治疗性细胞组合物的效力的方法
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
JP2024525910A (ja) 2021-07-19 2024-07-12 リペアロン イミュノ ゲーエムベーハー 多能性幹細胞から免疫細胞の集団を作製する方法
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
KR20250121074A (ko) 2022-12-09 2025-08-11 주노 쎄러퓨티크스 인코퍼레이티드 홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
AU2024230609A1 (en) 2023-02-28 2025-09-04 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
CN117448255B (zh) * 2023-09-28 2024-12-31 深圳市龙华区人民医院 S2饲养细胞、制备方法及其应用
WO2025109111A1 (en) * 2023-11-22 2025-05-30 Immudex Aps Immune cell activating multimers
KR102824339B1 (ko) * 2024-07-01 2025-06-26 현대자동차주식회사 배터리 제어 장치 및 그 방법

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
DE3583940D1 (de) 1984-10-02 1991-10-02 Harry M Meade Herstellung von streptavidinaehnlichen polypeptiden.
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
WO1994029436A1 (en) 1993-06-04 1994-12-22 The United States Of America Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
EP0815121A4 (en) 1995-02-09 1999-09-01 Univ Washington MODIFIED AFFINITY STREPTAVIDINE
AU5917796A (en) 1995-04-11 1997-04-09 Trustees Of Boston University Streptavidin mutants
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
EP0977770A4 (en) 1997-03-14 2000-04-05 Univ Boston DIFFERENTLY FLAVORED STREPTAVIDINE
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
US6664042B1 (en) 1999-01-26 2003-12-16 Cornell Research Foundation, Inc. Determining viral load in double negative T cells
SI1149114T1 (sl) * 1999-02-03 2014-08-29 Amgen Inc. Polipeptidi, vkljuäśeni v imunskem odgovoru
EP1147176B1 (en) * 1999-02-04 2009-12-16 Pluristem Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
EP1227321A1 (en) * 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
DE50312184D1 (de) 2002-03-01 2010-01-14 Volker A Erdmann Streptavidin-bindungspeptid
US7754155B2 (en) 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
WO2003090781A1 (en) 2002-04-23 2003-11-06 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
EP1569510B1 (en) 2002-09-27 2011-11-02 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
CA2565581C (en) 2003-05-02 2014-07-08 Insception Bioscience, Inc. Apparatus and methods for amplification of blood stem cell numbers
EP1623017B1 (en) * 2003-05-08 2010-09-15 Life Technologies Corporation Generation and isolation of antigen-specific t cells
US20080050795A1 (en) 2003-11-20 2008-02-28 Biosensor Applications Sweden Ab Mixture Of At Least Two Different Antibodies Specific For Predetermined Antigens And Use Of The Mixture
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
US7776583B2 (en) 2004-06-03 2010-08-17 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
CN101044405B (zh) 2004-10-15 2015-06-10 金克克国际有限公司 竞争性示差筛选
WO2006058226A2 (en) * 2004-11-24 2006-06-01 The Trustees Of Boston University Modified dimeric streptavidins and uses thereof
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US7704708B2 (en) * 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
WO2007117602A2 (en) 2006-04-07 2007-10-18 Biogen Idec Ma Inc. Isolation and use of human regulatory t cells
US20070238169A1 (en) * 2006-04-11 2007-10-11 The Board Of Trustees Of The Leland Stanford Junior University Cell sorter and culture system
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
KR101454287B1 (ko) 2006-10-17 2014-11-04 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
CA2668001C (en) 2006-11-02 2016-05-03 Kyowa Medex Co., Ltd. A method of immunoassaying a component to be measured in a sample containing hemoglobin
CN101622340A (zh) 2006-11-15 2010-01-06 茵维特罗根戴纳股份公司 生物素化合物与支持物可逆结合的方法
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
WO2008118476A2 (en) * 2007-03-26 2008-10-02 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
CN101802195B (zh) 2007-08-20 2012-10-24 内克斯特伊拉股份公司 pⅦ噬菌体展示
US8747290B2 (en) 2007-12-07 2014-06-10 Miltenyi Biotec Gmbh Centrifuge for separating a sample into at least two components
EA201400710A1 (ru) 2008-01-18 2015-03-31 Президент Энд Феллоуз Оф Гарвард Колледж Способы детекции признаков заболеваний или состояний в жидкостях организма
ES2666667T3 (es) 2008-01-29 2018-05-07 Fred Hutchinson Cancer Research Center Identificación de células T CD8+ que son CD161 hi y/o IL-18R (alfa) hi y tienen una capacidad de evacuación rápida de fármacos
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
US20120214187A1 (en) * 2009-11-02 2012-08-23 Ffina Biolutions, Llc Method for Enhancing the Sensitivity of Antibody Based Assays
US20120321665A1 (en) * 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
EP2363501A1 (en) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Method for isolating target cells
CA2806440A1 (en) 2010-08-06 2012-02-09 Ludwig-Maximilians-Universitaet Muenchen Identification of t cell target antigens
WO2012058627A2 (en) 2010-10-29 2012-05-03 Miqin Zhang Pre-targeted nanoparticle system and method for labeling biological particles
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
PL2734538T5 (pl) 2011-07-18 2025-11-12 Iba Lifesciences Gmbh Sposób odwracalnego barwienia komórki docelowej
US9353161B2 (en) 2011-09-13 2016-05-31 Uti Limited Partnership Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins
EP2817625B1 (en) 2012-02-23 2025-01-01 Juno Therapeutics GmbH Chromatographic isolation of cells and other complex biological materials
UA114108C2 (uk) * 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
CA2878862C (en) 2012-07-13 2023-01-10 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced t cells for administration
IL237315B (en) 2012-08-20 2022-07-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
US10065996B2 (en) 2012-11-16 2018-09-04 Iba Gmbh Streptavidin muteins and methods of using them
CN103305464B (zh) 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
US9698876B2 (en) 2013-07-23 2017-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Transmission mode allocation in LTE networks
PT3083671T (pt) 2013-12-20 2020-12-24 Hutchinson Fred Cancer Res Moléculas efetoras quiméricas etiquetadas e recetores destas
PL3888674T3 (pl) 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
ES2892927T3 (es) * 2014-04-16 2022-02-07 Juno Therapeutics Gmbh Métodos, kits y aparatos para expandir una población de células
EP3134514B1 (en) 2014-04-23 2019-09-18 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
JP6661544B2 (ja) 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
DK3134095T3 (da) 2014-04-25 2020-06-29 Bluebird Bio Inc Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
CA2945414C (en) * 2014-04-30 2023-05-09 Iba Gmbh Method of isolating a target cell
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MX395154B (es) 2015-10-22 2025-03-25 Juno Therapeutics Gmbh Métodos, kits, agentes y aparatos para transducción.
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
CA3007262A1 (en) 2015-12-03 2017-06-08 Lucas James Thompson Modified chimeric receptors and related compositions and methods
BR112019022356A2 (pt) 2017-04-27 2020-05-26 Juno Therapeutics Gmbh Reagentes de partícula oligoméricos e métodos de uso dos mesmos
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same

Also Published As

Publication number Publication date
IL280738B (en) 2022-07-01
NZ763587A (en) 2021-11-26
SA516380090B1 (ar) 2021-10-21
JP6696969B2 (ja) 2020-05-20
JP2017513524A (ja) 2017-06-01
SA520412247B1 (ar) 2023-12-05
EP3988920A1 (en) 2022-04-27
MY184699A (en) 2021-04-18
CA3176848A1 (en) 2015-10-22
IL293587B2 (en) 2025-02-01
AU2022200527B9 (en) 2025-05-08
CN106414724A (zh) 2017-02-15
RU2016144724A (ru) 2018-05-18
MX2020014089A (es) 2021-07-21
CA2945889C (en) 2024-01-09
PH12020551028A1 (en) 2021-06-07
IL280738A (en) 2021-03-25
JP2020124210A (ja) 2020-08-20
AU2015248786B2 (en) 2021-11-04
NZ763583A (en) 2021-10-29
MX380519B (es) 2025-03-12
KR102459384B1 (ko) 2022-10-26
EP3132247B1 (en) 2021-08-18
PL3132247T3 (pl) 2022-01-03
RU2735640C2 (ru) 2020-11-05
IL293587A (en) 2022-08-01
PH12016502017A1 (en) 2017-01-09
RU2020133435A (ru) 2020-12-01
KR20170003932A (ko) 2017-01-10
NZ725213A (en) 2021-10-29
PH12016502017B1 (en) 2017-01-09
HRP20211430T1 (hr) 2021-12-10
US20170037368A1 (en) 2017-02-09
CA2945889A1 (en) 2015-10-22
CN111961647A (zh) 2020-11-20
HUE056852T2 (hu) 2022-03-28
BR112016024072A2 (pt) 2017-10-10
NZ763585A (en) 2021-10-29
IL248360A0 (en) 2016-11-30
LT3132247T (lt) 2021-12-10
PT3132247T (pt) 2021-11-03
WO2015158868A3 (en) 2016-01-28
JP2023062124A (ja) 2023-05-02
BR112016024072B1 (pt) 2021-02-09
US11274278B2 (en) 2022-03-15
RS62471B1 (sr) 2021-11-30
SMT202100600T1 (it) 2021-11-12
SG10201808491UA (en) 2018-11-29
EP3132247A2 (en) 2017-02-22
AU2015248786A1 (en) 2016-11-03
WO2015158868A2 (en) 2015-10-22
AU2022200527B2 (en) 2025-03-27
KR20220150988A (ko) 2022-11-11
RU2735640C9 (ru) 2021-02-08
US20220195388A1 (en) 2022-06-23
JP2025060756A (ja) 2025-04-10
JP7762499B2 (ja) 2025-10-30
MX2016013493A (es) 2017-05-10
RU2016144724A3 (cg-RX-API-DMAC7.html) 2018-12-12
IL293587B1 (en) 2024-10-01
IL248360B (en) 2021-02-28
SA521421882B1 (ar) 2023-11-19
AU2022200527A1 (en) 2022-02-17
ES2892927T3 (es) 2022-02-07
KR102714469B1 (ko) 2024-10-11
SG11201608557UA (en) 2016-11-29
CN116656605A (zh) 2023-08-29
DK3132247T3 (da) 2021-10-11
SI3132247T1 (sl) 2021-12-31

Similar Documents

Publication Publication Date Title
CY1124717T1 (el) Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων
CY1123220T1 (el) Πρωτεϊνες συνδεσης anti-lag-3
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
MX2020000481A (es) Uso de proteína cas, método para detectar moléculas de ácido nucleico objetivo y kit.
CL2017002604A1 (es) Sondas duales silenciadoras
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
EP4300100A3 (en) Reagent storage in an assay device
MY170164A (en) Aptamer-based multiplexed assays
EP3757225A3 (en) Pancreatic cancer detection kit or device, and detection method
BR112016008970A2 (pt) Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra
SA518400078B1 (ar) مصفوفة مولد ضد
BR112014018995A2 (pt) Sistemas para executar ensaio automatizado
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
AU2013252445A8 (en) Assays, methods and apparatus for assessing RNA disruption
MX2017001134A (es) Composiciones y metodos para la deteccion y analisis de tuberculosis micobacteriana.
TR201907737T4 (tr) Test numunesi desteği ve çarpışma testi aparatı ve destek kullanılarak yapısal elemanın çarpışma testi yöntemi.
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
BR112019006862A2 (pt) dispositivo de análise e método para testagem de uma amostra
CY1123180T1 (el) Συστημα ανιχνευσης που αξιοποιει αλυσιδωτη αντιδραση πολυμερασης
BR112017008393A2 (pt) aparelho e sistema para amplificação de ácido nucleico
BR112017002575A2 (pt) método para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo, kit e sistema para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo
MX2021015057A (es) Anticuerpos anti-talen y usos de los mismos.
MX376879B (es) Metodos y sistemas para la deteccion rapida de microorganismos utilizando anticuerpos libres.